Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.031
-0.069 (-6.27%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Immuron Employees
Immuron had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$712,477
Profits / Employee
-$442,735
Market Cap
7.35M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Curis | 24 |
| Bolt Biotherapeutics | 23 |
| BioVie | 13 |
| Processa Pharmaceuticals | 12 |
| Ensysce Biosciences | 10 |
| AEON Biopharma | 8 |
| MetaVia | 8 |
IMRN News
- 25 days ago - Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - GlobeNewsWire
- 5 weeks ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 3 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 4 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 5 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 5 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 7 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 7 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire